These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26748742)

  • 41. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products.
    Mikaelsson M; Oswaldsson U
    Semin Thromb Hemost; 2002 Jun; 28(3):257-64. PubMed ID: 12098085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards.
    Morfini M; Cinotti S; Bellatreccia A; Paladino E; Gringeri A; Mannucci PM;
    J Thromb Haemost; 2003 Nov; 1(11):2283-9. PubMed ID: 14629459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua.
    Robinson MM; George LA; Carr ME; Samelson-Jones BJ; Arruda VR; Murphy JE; Rybin D; Rupon J; High KA; Tiefenbacher S
    J Thromb Haemost; 2021 May; 19(5):1212-1218. PubMed ID: 33636038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators.
    Dodt J; Hubbard AR; Wicks SJ; Gray E; Neugebauer B; Charton E; Silvester G
    Haemophilia; 2015 Jul; 21(4):543-9. PubMed ID: 25623631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
    Adamkewicz JI; Chen DC; Paz-Priel I
    Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
    Berntorp E; Shapiro AD; Waters J; Astermark J
    Haemophilia; 2014 Sep; 20(5):e362-4. PubMed ID: 25156443
    [No Abstract]   [Full Text] [Related]  

  • 47. A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.
    Tiefenbacher S; Clausen WHO; Hansen M; Lützhøft R; Ezban M
    Haemophilia; 2019 Sep; 25(5):893-901. PubMed ID: 31294905
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
    Matsumoto T; Shima M; Takeyama M; Yoshida K; Tanaka I; Sakurai Y; Giles AR; Yoshioka A
    J Thromb Haemost; 2006 Feb; 4(2):377-84. PubMed ID: 16420569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Variability in combinations of APTT reagent and substrate plasma for a one-stage clotting assay to measure factor VIII products.
    Suzuki A; Suzuki N; Kanematsu T; Okamoto S; Suzuki N; Tamura S; Kikuchi R; Katsumi A; Kojima T; Matsushita T
    Int J Lab Hematol; 2024 Aug; 46(4):705-713. PubMed ID: 38426662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
    Gu JM; Ramsey P; Evans V; Tang L; Apeler H; Leong L; Murphy JE; Laux V; Myles T
    Haemophilia; 2014 Jul; 20(4):593-600. PubMed ID: 24471985
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.
    Sommer JM; Moore N; McGuffie-Valentine B; Bardan S; Buyue Y; Kamphaus GD; Konkle BA; Pierce GF
    Haemophilia; 2014 Mar; 20(2):294-300. PubMed ID: 24261554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
    Van den Bossche D; Peerlinck K; Jacquemin M
    Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Measurement of B-domain-deleted ReFacto AF activity with a product-specific standard is affected by choice of reagent and patient-specific factors.
    Jacquemin M; Vodolazkaia A; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K
    Haemophilia; 2018 Jul; 24(4):675-682. PubMed ID: 28124445
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity measurements of dalcinonacog alfa.
    Williams SC; Gray E
    Haemophilia; 2020 Mar; 26(2):346-353. PubMed ID: 32142203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects.
    Favaloro EJ; Gilmore G; Bonar R; Dean E; Arunachalam S; Mohammed S; Baker R
    Haemophilia; 2020 Mar; 26(2):354-362. PubMed ID: 31962376
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
    Mazurier C; Parquet-Gernez A; Goudemand M
    Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
    Kitchen S; Katterle Y; Beckmann H; Maas Enriquez M
    J Thromb Haemost; 2016 Jun; 14(6):1192-9. PubMed ID: 27002680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.
    Atsou S; Furlan F; Duchemin J; Ellouze S; Sourdeau É; Launois A; Roussel-Robert V; Stieltjes N; Combe S; Fontenay M; Curis E; Jourdi G
    Eur J Pharmacol; 2021 Jan; 891():173764. PubMed ID: 33249076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.